ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which selected by an inhouse editor and fully peer-reviewed by external reviewers. It distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology and Hepatology |
Manuscript Type |
Clinical Trials Study |
Article Title |
Phase Ⅰ clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Jie Shen, Li-Feng Wang, Zheng-Yun Zou, Wei-Wei Kong, Jing Yan, Fan-Yan Meng, Fang-Jun Chen, Juan Du, Jie Shao, Qiu-Ping Xu, Hao-Zhen Ren, Ru-Tian Li, Jia Wei, Xiao-Ping Qian and Bao-Rui Liu |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
National Natural Science Foundation of China |
81401969 |
Jiangsu Provincial Medical Youth Talent |
QNRC2016043 |
the Key Medical Science and Technology Development Project of Nanjing |
ZKX16032 |
|
Corresponding Author |
Bao-Rui Liu, MD, PhD, Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, 321 Zhongshan Rd, Nanjing 210008, Jiangsu Province, China. baoruiliu@nju.edu.cn |
Key Words |
Personalized peptide vaccination; TOMO radiotherapy; Cytotoxic lymphocytes; Hepatocellular carcinoma |
Core Tip |
Advanced hepatocellular carcinoma (HCC) is a challenging disease to treat because of its advanced stage at diagnosis and rapid progression. We developed a new treatment modality, cellular immune therapy based on personalized peptide vaccination combined with radiotherapy, to treat advanced HCC. It integrates personalized peptide vaccination in tumor immunotherapy, takes full advantages of the immune modulation of radiotherapy, promotes tumor cells to release antigens and results in a more effective therapeutic strategy with regard to local and systemic control. |
Publish Date |
2017-08-07 09:17 |
Citation |
Shen J, Wang LF, Zou ZY, Kong WW, Yan J, Meng FY, Chen FJ, Du J, Shao J, Xu QP, Ren HZ, Li RT, Wei J, Qian XP, Liu BR. Phase Ⅰ clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma. World J Gastroenterol 2017; 23(29): 5395-5404 |
URL |
http://www.wjgnet.com/1007-9327/full/v23/i29/5395.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v23.i29.5395 |